Malaysia
Search
Sign In
Change Password
Points
Sign Out
Rheumatology
Top Medical News
Topical ketoprofen and diclofenac yield comparable analgesic effects in the treatment of pain in patients with knee osteoarthritis, with ketoprofen having a favourable safety profile, as shown in a phase III study.
Among women with rheumatoid arthritis (RA) and/or inflammatory bowel disease (IBD) undergoing assisted reproductive technology (ART) procedures, embryo transfer at the blastocyst stage and corticosteroid use prior to ART appear to improve chances of a live birth, a study has found.
In patients with rheumatoid arthritis (RA), comorbidities tend to result in higher annual healthcare expenditure, lower likelihood of employment, higher rates of absenteeism, and lower income, according to a study. Heart failure (HF), despite its lower prevalence, is associated with the highest incremental expenditure and lowest chance of employment compared with other common comorbid conditions.
Use of apremilast does not provide any clinical benefit in patients with active ankylosing spondylitis (AS), but the safety and tolerability of this treatment are consistent with its known profile, reports a study.
In patients with ankylosing spondylitis (AS), treatment with secukinumab leads to improvement in enthesitis at overall Maastricht AS Enthesitis Score (MASES) and axial sites, results of a recent study have shown.
Children whose parents smoke are likely to develop seropositive rheumatoid arthritis (RA) as adults, regardless of their smoking habits, a study suggests.
Some factors associated with rheumatoid arthritis (RA), such as treatment with leflunomide, azathioprine, and prednisolone and concomitant obstructive lung disease, can elevate the risk of tuberculosis (TB) in biologic-naïve patients with RA, reveals a study.
Special Reports
At the International Osteoporosis Foundation Regionals – 6th Asia-Pacific Osteoporosis Meeting in Singapore, Professor Olivier Bruyère shared about the algorithm for the management of knee OA by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). MIMS Doctor also spoke to Professor Jean-Yves Reginster, president of ESCEO about this algorithm and the role of SYSADOAs in the control of pain and prevention of disease progression.
Conference Reports
The use of apremilast consistently reduced the number and pain due to oral ulcers in both men and women with active Behçet’s syndrome, according to a subgroup analysis of the RELIEF* study presented at EULAR 2021.
Analysis of the German COVID-19 registry suggests that patients with rheumatic or musculoskeletal diseases (RMDs) who are treated with tumour necrosis factor (TNF) inhibitors appear to be at lower risk of severe outcomes of COVID-19 compared with those treated with other (non-TNF inhibitor) immunomodulatory treatments (OIDs).
Certain therapies used for rheumatic diseases, including rituximab, are associated with worse outcomes for COVID-19 and reduced immune response after COVID-19 vaccination in patients with rheumatic diseases, according to two studies presented at the virtual EULAR 2021 Congress.
Treatment with the fully human anti-IL17 monoclonal antibody secukinumab resulted in fewer, and a longer time to, disease flares in children and adolescents with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA), results of the phase III JUNIPERA trial showed.
Treatment with guselkumab improved response rates in patients with active psoriatic arthritis (PsA) who had inadequate responses to tumour necrosis factor (TNF) inhibitors, according to the COSMOS* study presented at EULAR 2021.
Data from the EULAR COVID-19 Vaccination (COVAX) Registry showed that available COVID-19 vaccines were safe and well tolerated in patients with rheumatic and musculoskeletal diseases (RMDs).
The humanized immunoglobulin G1 monoclonal antibody risankizumab led to significant improvements in patients with active psoriatic arthritis (PsA), including those with insufficient response or intolerance to one or two biologic therapies or to at least one DMARD*, according to the results of the phase III KEEPsAKE2 trial presented at EULAR 2021.
